EICHORPublic-registry site landscape for NCT04800237, “Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety”, a Performance Anxiety study sponsored by Vanda Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04800237 (registry record) |
| Study title | Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of VQW-765 in Patients With Performance Anxiety |
| Sponsor | Vanda Pharmaceuticals |
| Condition(s) | Performance Anxiety |
| Phase | PHASE2 |
| Listed sites | 15 |
| Intervention(s) | VQW-765, Placebo |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT04800237.
Eichor generates a preliminary site-risk snapshot for NCT04800237 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
